Tmic-28. Title: An Immune-Related, Sex-Specific T-Cell Signature In Glioblastoma Microenvironment With Prognostic Impact
Giulia Romagnoli,Martina Offi,Imerio Capone,Andrea Tavilla,Irene Canini,Caterina Lapenta,Mariachiara Buccarelli,Martina Giordano,Valentina Tirelli,Massimo Sanchez,Alessandra Fragale,Stefano Giannetti,Giovanni Maria Ceccarelli,Rina Di Bonaventura,Francesco Doglietto,Alessandro Olivi,Liverana Lauretti,Mauro Biffoni,Lucia Ricci-Vitiani,Roberto Pallini,Lucia Gabriele,Quintino Giorgio D’Alessandris
DOI: https://doi.org/10.1093/neuonc/noae165.1206
2024-11-29
Neuro-Oncology
Abstract:BACKGROUNDGlioblastoma, IDH-wildtype (GBM), is the most prevalent and aggressive primary brain cancer with a poor prognosis. Immune checkpoint inhibitors (ICIs) have been explored in GBM with limited success, highlighting the need for a better understanding of the tumor microenvironment (TME). This study investigated whether the expression of specific immune checkpoints on tissue-resident memory T cells (Trm) predicts patient outcomes. METHODSIn a single cohort observational study, tumor samples from 45 histologically confirmed GBM patients were processed to obtain single-cell suspensions. Multiparametric flow cytometry was used to analyze the correlation of Trm phenotypes with overall survival (OS) and progression-free survival (PFS). Univariate and multivariate analyses were conducted to assess the prognostic significance of Trm subsets. RESULTSLow frequency of exausted Trm expressing programmed cell death protein 1 (PD1) and T cell immunoglobulin and mucin domain-containing protein 3 (TIM3) was associated with better clinical outcomes. Multivariate analysis identified low CD8+CD103+PD1+TIM3+ Trm and Karnofsky performance status (KPS) ≥70 as the most significant independent prognostic factors for longer OS (hazard ratios—HR [95%CI]: 0.14 [0.04–0.52] p < 0.001, 0.39 [0.16–0.96] p = 0.04, respectively). Additionally, younger patients (<63 years) and males had distinct immune profiles affecting prognosis. Notably, the proportion of exausted CD8+CD103+PD1+ Trms had a prognostic correlate only in male patients, consistent with findings by other groups on the existance of gender-specific immune TME in GBM. CONCLUSIONSFurther exploration of Trm-based immune profiling has the potential to shed light on GBM resistance to ICIs and to help in personalizing treatment strategies.
oncology,clinical neurology